Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PGK1 | P00558 | 1/20 | 0.53 |
| ▸ | PGK2 | P07205 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5389595 | 0.92 | ADORA3 (0.70) | ADORA3ADORA1ADORA2A | |
| SCHEMBL5392557 | 0.91 | ADORA3 (0.53) | ADORA3ADORA1ADORA2ASLC29A1 | |
| SCHEMBL5384034 | 0.91 | ADORA3 (0.65) | ADORA3ADORA1ADORA2A | |
| SCHEMBL5380309 | 0.91 | ADORA2A (0.52) | ADORA3ADORA1ADORA2A | |
| SCHEMBL6257480 | 0.91 | ADORA2A (0.52) | ADORA3ADORA1ADORA2A | |
| SCHEMBL5380408 | 0.90 | ADORA3 (0.65) | ADORA3ADORA1ADORA2ASLC29A1PGK1 | |
| SCHEMBL5384061 | 0.90 | ADORA3 (0.64) | ADORA3ADORA1ADORA2A | |
| SCHEMBL5390140 | 0.88 | ADORA3 (0.54) | ADORA3ADORA1ADORA2A | |
| SCHEMBL5380458 | 0.88 | ADORA1 (0.54) | ADORA3ADORA1ADORA2A | |
| SCHEMBL5397394 | 0.87 | ADORA3 (0.54) | ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262176-B2 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1414837-B1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040116376-A1 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20030078232-A1 | Adenosine receptor A3 agonists | CV THERAPEUTICS, INC. | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078232-A1 | Adenosine receptor A3 agonists | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA1 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.